Monoclonal antibodies for the treatment of osteoporosis (Q38068600)

28 August 2017

1 reference

title

Monoclonal antibodies for the treatment of osteoporosis (English)

1 reference

28 August 2017

0 references

1 reference

E Michael Lewiecki

1 reference

28 August 2017

language of work or name

English

0 references

publication date

19 December 2012

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

183-196

1 reference

Hip fractures in the elderly: a world-wide projection

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Osteoporosis prevention, diagnosis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Perspective. How many women have osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

The crippling consequences of fractures and their impact on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Hip fracture in women without osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Longitudinal trends in use of bone mass measurement among older americans, 1999-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Compliance with drug therapies for the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

The impact of compliance with osteoporosis therapy on fracture rates in actual practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Biology without walls: the novel endocrinology of bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Critical role of beta3 integrin in experimental postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Osteoblastogenesis regulation signals in bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

CREB mediates brain serotonin regulation of bone mass through its expression in ventromedial hypothalamic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Osteoblasts in osteoporosis: past, emerging, and future anabolic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

A Rate-Limiting Role for Dickkopf-1 in Bone Formation and the Remediation of Bone Loss in Mouse and Primate Models of Postmenopausal Osteoporosis by an Experimental Therapeutic Antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Monoclonal antibody therapeutics: history and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

New targets for intervention in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.740006

10.1517/14712598.2012.740006

21 January 2018

Identifiers

DOI

1 reference

release_7djdrub4xvdppkpy4lhkbqlrv4

28 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7djdrub4xvdppkpy4lhkbqlrv4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference